Physician profile
Danilo B Corales
NPI 1013951771
$17,129.19
in general payments reported to CMS, 2019-2025
63 companies · $2,260 in 2025
The $2,260 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,668 · 2020: $2,236 · 2021: $2,800 · 2022: $2,446 · 2023: $2,070 · 2024: $2,649 · 2025: $2,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,967 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,967.49 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,336.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,947.83 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $1,418.36 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,063.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $926.00 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $726.57 | 2019-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $697.59 | 2019-2024 | Myrbetriq, Veozah |
| Amgen INC. | $686.91 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $659.53 | 2019-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $652.68 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $557.75 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $462.27 | 2019-2025 | Rexulti |
| Abbott Laboratories | $373.34 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $369.38 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $356.04 | 2019-2025 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danilo Corales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.